Literature DB >> 11224854

Trimethoprim-sulfamethoxazole and fulminant ehrlichiosis.

R K Brantley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11224854     DOI： 10.1097/00006454-200102000-00028

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


× No keyword cloud information.
  6 in total

Review 1.  Tick-borne infections in children: epidemiology, clinical manifestations, and optimal management strategies.

Authors:  Steven C Buckingham
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 2.  Human ehrlichiosis and anaplasmosis.

Authors:  Nahed Ismail; Karen C Bloch; Jere W McBride
Journal:  Clin Lab Med       Date:  2010-03       Impact factor: 1.935

3.  Ehrlichia infection of the central nervous system.

Authors:  Igen Hongo; Karen C Bloch
Journal:  Curr Treat Options Neurol       Date:  2006-05       Impact factor: 3.972

4.  Patient characteristics, treatment patterns, and outcomes of Rickettsial diseases among a commercially insured population in the United States, 2005-2017.

Authors:  Alison M Binder; Paige A Armstrong
Journal:  Sci Rep       Date:  2021-09-15       Impact factor: 4.996

5.  Myocarditis after trimethoprim/sulfamethoxazole treatment for ehrlichiosis.

Authors:  Seema U Nayak; Gary L Simon
Journal:  Emerg Infect Dis       Date:  2013-12       Impact factor: 6.883

6.  Assessment of Risk Factors and Outcomes of Severe Ehrlichiosis Infection.

Authors:  Kevin Kuriakose; April C Pettit; Jonathan Schmitz; Abelardo Moncayo; Karen C Bloch
Journal:  JAMA Netw Open       Date:  2020-11-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.